BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Henderson MX, Sedor S, McGeary I, Cornblath EJ, Peng C, Riddle DM, Li HL, Zhang B, Brown HJ, Olufemi MF, Bassett DS, Trojanowski JQ, Lee VMY. Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult. Neuron 2020;105:822-836.e7. [PMID: 31899072 DOI: 10.1016/j.neuron.2019.12.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Riboldi GM, Vialle RA, Navarro E, Udine E, de Paiva Lopes K, Humphrey J, Allan A, Parks M, Henderson B, Astudillo K, Argyrou C, Zhuang M, Sikder T, Oriol Narcis J, Kumar SD, Janssen W, Sowa A, Comi GP, Di Fonzo A, Crary JF, Frucht SJ, Raj T. Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson's disease. Mol Neurodegener 2022;17:52. [PMID: 35978378 DOI: 10.1186/s13024-022-00554-8] [Reference Citation Analysis]
2 Wang L, Lin G, Zuo Z, Li Y, Byeon SK, Pandey A, Bellen HJ. Neuronal activity induces glucosylceramide that is secreted via exosomes for lysosomal degradation in glia. Sci Adv 2022;8:eabn3326. [DOI: 10.1126/sciadv.abn3326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Huang J, Li C, Shang H. Astrocytes in Neurodegeneration: Inspiration From Genetics. Front Neurosci 2022;16:882316. [DOI: 10.3389/fnins.2022.882316] [Reference Citation Analysis]
4 Vrijsen S, Vrancx C, Del Vecchio M, Swinnen JV, Agostinis P, Winderickx J, Vangheluwe P, Annaert W. Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites. Front Neurosci 2022;16:900338. [DOI: 10.3389/fnins.2022.900338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Polinski NK, Martinez TN, Ramboz S, Sasner M, Herberth M, Switzer R, Ahmad SO, Pelligrino LJ, Clark SW, Marcus JN, Smith SM, Dave KD, Frasier MA. The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models. Dis Model Mech 2022;15:dmm049192. [PMID: 35419585 DOI: 10.1242/dmm.049192] [Reference Citation Analysis]
6 Filippi M, Balestrino R, Basaia S, Agosta F. Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review. Mov Disord 2022. [PMID: 35521899 DOI: 10.1002/mds.29047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Gegg ME, Menozzi E, Schapira AH. Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments. Neurobiology of Disease 2022;166:105663. [DOI: 10.1016/j.nbd.2022.105663] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
8 Kumar ST, Mahul-Mellier AL, Hegde RN, Rivière G, Moons R, Ibáñez de Opakua A, Magalhães P, Rostami I, Donzelli S, Sobott F, Zweckstetter M, Lashuel HA. A NAC domain mutation (E83Q) unlocks the pathogenicity of human alpha-synuclein and recapitulates its pathological diversity. Sci Adv 2022;8:eabn0044. [PMID: 35486726 DOI: 10.1126/sciadv.abn0044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Smith L, Schapira AHV. GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells 2022;11:1261. [DOI: 10.3390/cells11081261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
10 Vendruscolo M. Lipid Homeostasis and Its Links With Protein Misfolding Diseases. Front Mol Neurosci 2022;15:829291. [DOI: 10.3389/fnmol.2022.829291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Domingues R, Sant’anna R, da Fonseca ACC, Robbs BK, Foguel D, Outeiro TF. Extracellular alpha-synuclein: Sensors, receptors, and responses. Neurobiology of Disease 2022. [DOI: 10.1016/j.nbd.2022.105696] [Reference Citation Analysis]
12 Beger AW, Dudzik B, Woltjer RL, Wood PL. Human Brain Lipidomics: Pilot Analysis of the Basal Ganglia Sphingolipidome in Parkinson’s Disease and Lewy Body Disease. Metabolites 2022;12:187. [DOI: 10.3390/metabo12020187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Van Den Berge N, Ulusoy A. Animal models of brain-first and body-first Parkinson's disease. Neurobiology of Disease 2022;163:105599. [DOI: 10.1016/j.nbd.2021.105599] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
14 Fredriksen K, Aivazidis S, Sharma K, Burbidge KJ, Pitcairn C, Zunke F, Gelyana E, Mazzulli JR. Pathological α-syn aggregation is mediated by glycosphingolipid chain length and the physiological state of α-syn in vivo. Proc Natl Acad Sci U S A 2021;118:e2108489118. [PMID: 34893541 DOI: 10.1073/pnas.2108489118] [Reference Citation Analysis]
15 Shang S, Zhang H, Feng Y, Wu J, Dou W, Chen YC, Yin X. Region-Specific Neurovascular Decoupling Associated With Cognitive Decline in Parkinson's Disease. Front Aging Neurosci 2021;13:770528. [PMID: 34867297 DOI: 10.3389/fnagi.2021.770528] [Reference Citation Analysis]
16 Milenkovic I, Blumenreich S, Futerman AH. GBA mutations, glucosylceramide and Parkinson's disease. Curr Opin Neurobiol 2021;72:148-54. [PMID: 34883387 DOI: 10.1016/j.conb.2021.11.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
17 Kurzawa-Akanbi M, Tammireddy S, Fabrik I, Gliaudelytė L, Doherty MK, Heap R, Matečko-Burmann I, Burmann BM, Trost M, Lucocq JM, Gherman AV, Fairfoul G, Singh P, Burté F, Green A, McKeith IG, Härtlova A, Whitfield PD, Morris CM. Altered ceramide metabolism is a feature in the extracellular vesicle-mediated spread of alpha-synuclein in Lewy body disorders. Acta Neuropathol 2021;142:961-84. [PMID: 34514546 DOI: 10.1007/s00401-021-02367-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
18 Vieira SRL, Schapira AHV. Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways. Free Radic Biol Med 2021;175:42-55. [PMID: 34450264 DOI: 10.1016/j.freeradbiomed.2021.08.230] [Reference Citation Analysis]
19 Wang C, Yang T, Liang M, Xie J, Song N. Astrocyte dysfunction in Parkinson's disease: from the perspectives of transmitted α-synuclein and genetic modulation. Transl Neurodegener 2021;10:39. [PMID: 34657636 DOI: 10.1186/s40035-021-00265-y] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
20 Lee CY, Menozzi E, Chau KY, Schapira AHV. Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes. J Neurochem 2021;159:826-39. [PMID: 34618942 DOI: 10.1111/jnc.15524] [Reference Citation Analysis]
21 Sharabi Y, Vatine GD, Ashkenazi A. Parkinson's disease outside the brain: targeting the autonomic nervous system. Lancet Neurol 2021;20:868-76. [PMID: 34536407 DOI: 10.1016/S1474-4422(21)00219-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Cosden M, Jinn S, Yao L, Gretzula CA, Kandebo M, Toolan D, Hatcher NG, Ma L, Lemaire W, Adam GC, Burlein C, Minnick C, Flick R, Watt ML, Mulhearn J, Fraley M, Drolet RE, Marcus JN, Smith SM. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. Neurobiol Dis 2021;159:105507. [PMID: 34509608 DOI: 10.1016/j.nbd.2021.105507] [Reference Citation Analysis]
23 Valek L, Tegeder I. Failure of Diphtheria Toxin Model to Induce Parkinson-Like Behavior in Mice. Int J Mol Sci 2021;22:9496. [PMID: 34502404 DOI: 10.3390/ijms22179496] [Reference Citation Analysis]
24 Gegg ME, Verona G, Schapira AHV. Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons. Hum Mol Genet 2020;29:1716-28. [PMID: 32391886 DOI: 10.1093/hmg/ddaa085] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
25 Macías-García D, Periñán MT, Muñoz-Delgado L, Jimenez-Jaraba MV, Labrador-Espinosa MÁ, Jesús S, Buiza-Rueda D, Méndez-Del Barrio C, Adarmes-Gómez A, Gómez-Garre P, Mir P. Serum lipid profile among sporadic and familial forms of Parkinson's disease. NPJ Parkinsons Dis 2021;7:59. [PMID: 34272400 DOI: 10.1038/s41531-021-00206-6] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
26 Bell R, Vendruscolo M. Modulation of the Interactions Between α-Synuclein and Lipid Membranes by Post-translational Modifications. Front Neurol 2021;12:661117. [PMID: 34335440 DOI: 10.3389/fneur.2021.661117] [Reference Citation Analysis]
27 Paul A, Jacoby G, Laor Bar-Yosef D, Beck R, Gazit E, Segal D. Glucosylceramide Associated with Gaucher Disease Forms Amyloid-like Twisted Ribbon Fibrils That Induce α-Synuclein Aggregation. ACS Nano 2021. [PMID: 34213307 DOI: 10.1021/acsnano.1c02957] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
28 Milán-Tomás Á, Fernández-Matarrubia M, Rodríguez-Oroz MC. Lewy Body Dementias: A Coin with Two Sides? Behav Sci (Basel) 2021;11:94. [PMID: 34206456 DOI: 10.3390/bs11070094] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Long H, Zheng W, Liu Y, Sun Y, Zhao K, Liu Z, Xia W, Lv S, Liu Z, Li D, He KW, Liu C. Wild-type α-synuclein inherits the structure and exacerbated neuropathology of E46K mutant fibril strain by cross-seeding. Proc Natl Acad Sci U S A 2021;118:e2012435118. [PMID: 33972418 DOI: 10.1073/pnas.2012435118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Borghammer P. The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline. J Parkinsons Dis 2021;11:455-74. [PMID: 33682732 DOI: 10.3233/JPD-202481] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
31 Panicker N, Ge P, Dawson VL, Dawson TM. The cell biology of Parkinson's disease. J Cell Biol 2021;220:e202012095. [PMID: 33749710 DOI: 10.1083/jcb.202012095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
32 Wang V, Kuo TT, Huang EY, Ma KH, Chou YC, Fu ZY, Lai LW, Jung J, Choi HI, Choi DS, Li Y, Olson L, Greig NH, Hoffer BJ, Chen YH. Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. ACS Pharmacol Transl Sci 2021;4:858-69. [PMID: 33860208 DOI: 10.1021/acsptsci.1c00013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Lee JY, Marian OC, Don AS. Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia. Neuromolecular Med 2021;23:1-24. [PMID: 33550528 DOI: 10.1007/s12017-021-08644-4] [Reference Citation Analysis]
34 García-Sanz P, M F G Aerts J, Moratalla R. The Role of Cholesterol in α-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease. Mov Disord 2021;36:1070-85. [PMID: 33219714 DOI: 10.1002/mds.28396] [Cited by in Crossref: 3] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
35 Wildburger NC, Hartke AS, Schidlitzki A, Richter F. Current Evidence for a Bidirectional Loop Between the Lysosome and Alpha-Synuclein Proteoforms. Front Cell Dev Biol 2020;8:598446. [PMID: 33282874 DOI: 10.3389/fcell.2020.598446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
36 Goriely A, Kuhl E, Bick C. Neuronal Oscillations on Evolving Networks: Dynamics, Damage, Degradation, Decline, Dementia, and Death. Phys Rev Lett 2020;125:128102. [PMID: 33016724 DOI: 10.1103/PhysRevLett.125.128102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
37 Menozzi E, Schapira AHV. Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease. CNS Drugs 2020;34:915-23. [PMID: 32607746 DOI: 10.1007/s40263-020-00746-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
38 Avenali M, Blandini F, Cerri S. Glucocerebrosidase Defects as a Major Risk Factor for Parkinson's Disease. Front Aging Neurosci 2020;12:97. [PMID: 32372943 DOI: 10.3389/fnagi.2020.00097] [Cited by in Crossref: 17] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
39 Stok R, Ashkenazi A. Lipids as the key to understanding α-synuclein behaviour in Parkinson disease. Nat Rev Mol Cell Biol 2020;21:357-8. [DOI: 10.1038/s41580-020-0235-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
40 Teil M, Arotcarena ML, Faggiani E, Laferriere F, Bezard E, Dehay B. Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts. Biomolecules 2020;10:E391. [PMID: 32138193 DOI: 10.3390/biom10030391] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]